ABEO$4.94
Chart
Performance
Key Stats
AI ABEO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldAbeona Therapeutics exhibits mixed signals across its fundamental and technical profiles. The company operates in a high-growth therapeutic area, but current financial performance, particularly revenue and profitability, suggests a speculative investment at this stage. Investors should consider the company's early-stage nature and the inherent risks of clinical development.
Thematic
Abeona Therapeutics is positioned in the rapidly advancing field of gene and cell therapies for rare and life-threatening diseases. The growing demand for novel treatments, advancements in genetic engineering, and increasing patient and physician awareness create a strong thematic tailwind.
Fundamental
Abeona Therapeutics is a clinical-stage company with no current revenue. Its financial statements reflect significant operating expenses and net losses, consistent with drug development. The company has a moderate debt level and relies on cash flow from financing activities to fund operations.
Technical
The stock is trading below its 50-day and 200-day moving averages, indicating a bearish to neutral short-term trend. Oscillators like RSI are in neutral territory, suggesting no immediate overbought or oversold conditions, but the overall trend suggests caution.
| Factor | Score |
|---|---|
| Gene and Cell Therapy Market Growth | 90 |
| Rare Disease Treatment Demand | 85 |
| Biopharmaceutical Innovation | 70 |
| Regulatory Landscape | 70 |
| Competition | 60 |
| Factor | Score |
|---|---|
| Valuation | 0 |
| Profitability | 0 |
| Growth | 0 |
| Balance Sheet Health | 60 |
| Cash Flow | 20 |
| Debt Level | 50 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Support & Resistance | 60 |
| Volume Confirmation | 70 |
| Short-term Oscillators | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Short-Term Momentum
The stock has shown positive performance over the past month (+12.17%) and 6 months (+21.7%), indicating recent investor interest and potential upward price trend.
Improving Cash Position
Total equity increased by $44.03M as of Q4 2024, and cash equivalents stood at $23.36M, suggesting a stable financial base. The company also managed to raise $104.14M in financing cash flow in FY2024, indicating access to capital.
Bearish Points (8)
Negative EPS and High P/S Ratios
The company has a negative EPS TTM (-0.63) and a high Price-to-Sales (P/S) ratio of 94.3 in 2023, indicating that the company is not currently profitable and is trading at a premium relative to its revenue.
Consistent Net Losses
The company has consistently reported net losses, with a net income of -51.59M in TTM and -63.73M in 2024. Net margins are also negative, indicating unprofitability.
Calendar
August 2025
12
Next Earnings Date
H: $-0.34
A: $-0.39
L: $-0.43
H: 152.00M
A: 21.71M
0Profile
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Seasonals
Price Target
19.93 USD
The 39 analysts offering 1 year price forecasts for ABEO have a max estimate of 27.50 and a min estimate of 11.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Direct competitor focused on gene therapies for severe genetic diseases, including rare blood disorders, using lentiviral vectors.
Weight: 93
Develops lentiviral gene therapies for rare lysosomal storage disorders, a key therapeutic area of focus for Abeona.
Weight: 92
A leading gene therapy company developing AAV-based treatments for severe rare diseases, including lysosomal storage diseases.
Weight: 90
Clinical-stage gene therapy company focused on rare pediatric diseases, including Fanconi Anemia and LAD-I, using both lentiviral and AAV vectors.